Two hundred patients taking varying L-thyroxine replacement doses were studied using a normal TRH test as the index of optimal replacement dose. The mean optimal dose was 141 flgfday. Normal serum T a and Ff:J were found in most patients, whatever the TRH response, and they are probably too unspecific. Serum T 4 and F'I'41 were elevated in many patients with a normal TRH response. A higher range for Ff41 of 102-166, although only 66· 5 %accurate, gave the best index of optimal L-thyroxine replacement of the single in-vitro tests.
T 4 T s FT 41 FTal TSH TRH TRH (n) 59 patients showed a normal TRH response (increment 3-20 mUll) and normal baseline TSH «7 mUll), except in three patients in whom it was in the range 7-11 mUll. TRH (-) 83 patients showed no significant TRH response (increment <3 mUll) and baseline TSH <7 mUll.
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Material and methods Hypothyroid patients on L-thyroxine replacement. I Serum thyroxine (T 4) and triiodothyronine (T:J are prescribed a wide variety of dose, often selected.-, were estimated by radioimmunoassay using a somewhat arbitrarily. The thyrotrophin releasing double antibody technique (reagents supplied by hormone (TRH) test provides a sensitive indicator Leeds Nuclear Medicine Department). Resin T a both of the ingestion of a small excess of thyroid uptake ratio (RT aU) was measured by gel filtration hormone-and of the presence of small decreases in on small reusable Sephadex columns! and was used thyroid hormone levels," while a constant daily to give free thyroxine and triiodothyronine indices replacement dose of L-thyroxine is accompanied by (FT 41 and FTal). Serum TSH was estimated by unchanging levels of serum thyroxine, triiodo-radioimmunoassay (Abbott Laboratories) before thyronine, and thyrotrophin stimulating hormone and -20 minutes after 200 flg TRH given intra-(TSH).s We report a series of 200 patients on venously," Reference ranges were as follows: L-thyroxine replacement at various fixed daily Mean ± 2 SD dosages. A diagnosis of primary hypothyroidism had 99· 5 ± 19·2 nmol/l been established by appropriate tests; the majority 2'39 ± 0'50 nmol/l of patients had become hypothyroid after 1S11 102'5 ± 21·2 therapy for hyperthyroidism. TRH tests were 2·46 ± 0'54 carried out, and a normal response to TRH, nearly always accompanied by a normal baseline TSR, was taken as the criterion of correct or optimal L-thyroxine dosage. The TRH results were compared with those of serum thyroxine assay, triiodothyronine, free thyroxine index, and free triiodothyronine index in order to determine the diagnostic accuracy, sensitivity, and specificity of each of these latter tests as indices of correct L-thyroxine dosage. The TRR test was also used to determine the proportion of patients receiving optimal L-thyroxine dosage and the size of the mean optimal dose. Two hundred patients with established hypothyroidism who had been prescribed doses of between 25 and 400 flg/day ofr.-thyroxine, unchanged for at least three months, and who appeared healthy and clinically euthyroid, were studied. 300 1 TRH(+)TRH(n)1RH(-) Table 3 shows the patients divided into TRH ( +), TRH (n), and TRH (-) groups. Each group is subdivided according to the Ff41 value, above, within, or below the reference range. Diagnostic sensitivity is given by the percentage of TRH (n) patients with normal Ff41 (numbers circled) and diagnostic specificity by the percentage of TRH ( +) and TRH (-) patients with appropriately abnormal Ff41 values (numbers in squares). The circled and squared figures indicate the numbers of patients in whom the Ff41 gave a correct value as judged by the TRH response; the sum of these correct values divided by the total number gives the diagnostic accuracy.
The same procedure was applied to the other tests, T 4' T 3' and Ff31. It was clear that the accuracy, and particularly the specificity, of all the simple in-vitro tests is rather poor, as judged by their ability to predict a normal TRH response. The data were therefore re-examined with a series of higher ranges for Ff 4 1, and a range of 102-166 was found to give the best diagnostic accuracy (Table 4 ). This higher range of FT41, with a mean of 134, agrees closely with the range of values in patients showing a normal TRH response ( Table 1 ).
The results of the above procedures, summarised in Table 4 Results in these three groups are summarised in Table 1 and in the Figure. In the TRH (n) group, values for T 3 and Ff31 are slightly below mean normal, and for T4and FT41 appreciably above mean normal, values.
The patients were also divided into five groups by thyroxine dose, as shown in Table 2 Mean Ff31 (and T a> in the 150 !Jog group was very close to normal mean, and Ff41 (and T4)appreciably raised. T3/T4 ratio decreases with increasing thyroxine dosage. Previous studies to determine optimal L-thyroxine replacement dose have usually employed the technique of adjusting the dose by increments of 25 or 50 ILg to find the dose giving a normal baseline TSH.6-S At this dose level one study "showed hyperresponse to TRH, while another" showed decreased response in about half the patients. In this study, the TRH test was selected as a means of studying the problem in a substantial number of patients already on established and unchanged thyroxine replacement. It was noted that the mean T 3 and T 4 hormone values were not linearly related to thyroxine dose (Fig. 1) ; the presence of some endogenous thyroid function was not excluded in our patients, but similar findings have been reported where effective thyroidal blockade with carbimazole was maintained. S A normal TRH response as the criterion for appropriate thyroxine replacement may be unobtainable in all patients, particularly using 50 ILg dose increments, and it may be regarded as an over-delicate index of correct dosage." The TRH test does, however, have the advantage of indicating whether the replacement dose is likely to be too high or too low, whereas a normal baseline TSH, using routine methods, does not discriminate between correct and excessive dosage. In this study, more than 40 % of the patients were taking higher than optimal dosage.
Mean values for FTsl (circles) and FT.I (squares) are shown for patients (a) sub-divided by u-thyroxine dose (closed symbols) and (b) sub-divided by TRH test (open symbols). Normal mean valuesfor both FTsfand FT.I are shown by the horizontal line.
A normal TRH response is probably a good index of correct replacement, and the mean dose of L-thyroxine in those patients showing a normal response is an indication of the mean optimal replacement dose. This mean value of 141 ILg is intermediate between the values of 115 7 and 169 6 found in previous studies. Compared with other studies, mean T 4 and FT41 at optimal replacement dose were rather more elevated, although they have previously been reported to be a little higher than in untreated euthyroid subjects. 6 -s Mean T 3 and FT31 in our study were only marginally below normal in patients with normal TRH response, in contrast to elevated values previously reported," This might be regarded as the best simple test for satisfactory thyroxine replacement, particularly since evidence suggests that control of TSH secretion in subjects on Squire and Gimlette thyroxine replacement is mediated by serum triiodothyronine concentration. S However, the specificities of serum T 3 and Ff31 (Table 4) were very low, and 87 % of all FT31 values were within the normal range.
Ff41 showed the highest overall accuracy assessed against the TRH test, and a further improvement was obtained if a somewhat higher range for FT41 was taken as normal for thyroxine-treated patients, although the accuracy reached only 66 %.
Ninety-four had FT41 within this higher range, of whom 39 showed a normal TRH response and three ofthese a slightly elevated baseline TSH (7-11 mU /1). While it is likely that the majority of patients with values within this higher range for FT41 were receiving a satisfactory dose of L-thyroxine, the TRH test may be useful in cases of doubt and probably deserves to be used more frequently in the assessment of correct t-thyroxine dose.
